Bausch Health Companies   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Costa Mesa CA United States (1959)

Organization Overview

First Clinical Trial
1999
NCT00002298
First Marketed Drug
1959
ergoloid mesylate
First NDA Approval
1961
chlordiazepoxide (librium)
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

BAUSCH | Bausch Health | Bausch Health Americas, Inc. | Bausch Health, Canada Inc. | Bausch Health Companies | Bausch Health Companies, INC. | Bausch Health Ireland Limited | BAUSCH HEALTH IRELAND LIMITED | BAUSCH LOMB IRELAND | ICN Biomedicals | ICN Pharmaceuticals | ICN Pharmaceuticals (v1) | ICN Pharmaceuticals (v2) | Medical Monitor, Valeant Pharmaceuticals | Ortho Dermatologics | Valeant | VALEANT | Valeant/Bausch & Lomb | VALEANT BERMUDA | Valeant Canada Limited | VALEANT INTL | VALEANT LUXEMBOURG | Valeant Pharmaceitucals | Valeant Pharmaceutical | Valeant Pharmaceutical NA | Valeant Pharmaceuticals | Valeant Pharmaceuticals/Bausch & Lomb Incorporated | Valeant Pharmaceuticals International, Inc. | Valeant Pharmaceuticals NA | Valeant Pharmaceuticals, NA | Valeant Pharmaceuticals North America LLC | VALEANT PHARM INTL | VALEANT PHARMS | VALEANT PHARMS INC | VALEANT PHARMS INTL | VALEANT PHARMS LLC | VALEANT PHARMS NORTH | Valeant Russia, LLC | Yvonne Romero